Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.54 |
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532753 | 0.96 | HTR1A (0.52) | HTR1AHTR2ADRD2 | |
| SCHEMBL13532750 | 0.88 | HTR1A (0.47) | HTR1AHTR2ADRD2DRD4SLC22A2 | |
| SCHEMBL13532766 | 0.84 | HTR2A (0.60) | HTR1AHTR2ADRD2DRD4ADRA1D | |
| SCHEMBL13532755 | 0.83 | PARP1 (0.52) | HTR1AHTR2ADRD2DRD4SLC22A2 | |
| SCHEMBL13532757 | 0.83 | HTR1A (0.51) | HTR1AHTR2ADRD2ADRA1ADRD3 | |
| SCHEMBL8797545 | 0.80 | KCNH2 (0.60) | HTR1AHTR2ADRD2DRD4HTR7 | |
| SCHEMBL8798000 | 0.80 | DRD2 (0.57) | HTR1AHTR2ADRD2DRD4HTR7 | |
| SCHEMBL8798047 | 0.78 | ADRA1A (0.67) | HTR1AHTR2ADRD2DRD4CYP1A2 | |
| SCHEMBL13532722 | 0.78 | HTR1A (0.59) | HTR1AHTR2ADRD2DRD4SLC22A2 | |
| SCHEMBL14762194 | 0.78 | ADRA1A (0.66) | HTR1AHTR2ADRD2DRD4CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | claimed |
| US-5591743-A | ANXIOLYTIC DRUGS OR HYPOTENSIVE AGENTS | PIERRE FABRE MEDICAMENT (FR) | 1997-01-07 | — | — | US | claimed |
| EP-0707571-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1996-04-24 | — | — | EP | claimed |
| WO-1995001965-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-19 | — | — | WO | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-0802915-A1 | CAMPTOTHECIN DERIVATIVES AND ITS MANUFACTURING METHOD | CHONG KUN DANG CORP (KR) | 1997-10-29 | — | — | EP | disclosed |
| EP-0707571-B1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0707571-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PF MEDICAMENT (FR) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001965-A1 | 3,5-DIOXO-(2H,4H)-1,2,4-TRIAZINE DERIVATIVES AS 5HT1A LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | HTR1A 7/4885HTR2A 5/4885DRD2 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.